How many insider trades does FilingIQ track for ACAD?

FilingIQ tracks 684 Form 4 insider transactions for ACAD (ACADIA PHARMACEUTICALS INC), covering filings from Jan 13, 2015 onwards. 51 of those were filed in the last 90 days.

Are ACAD insiders net buyers or net sellers?

Across the full Form 4 history for ACAD, 61 transactions (9%) were open-market purchases and 204 (30%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does ACAD insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is ACAD in?

ACADIA PHARMACEUTICALS INC (ACAD) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.18B.

ACAD insider trading

NasdaqGS Healthcare

ACADIA PHARMACEUTICALS INC — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

684

Last 90 days

Buys / sells

9% / 30%

Market cap

$4.18B

About ACADIA PHARMACEUTICALS INC

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin which completed Phase III clinical trial to treat the negative symptoms of schizophrenia; ACP-101, which completed phase III clinical trial for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 that completed phase II clinical trial for the treatment of Alzheimer's disease psychosis and Lewy Body Dementia with psychosis; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; ACP-211 that is in phase I clinical trial for the treatment of treatment-resistant depression; ACP-2591 that is in Phase I development for Rett syndrome and Fragile X syndrome; and ACP-271, a GPR88 agonist used in evaluation of neurology and is in the IND-enabling stage. The company has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Company website: www.acadia.com

ACAD insider activity at a glance

FilingIQ has scored 684 insider transactions for ACAD since Jan 13, 2015. The most recent filing in our index is dated May 4, 2026.

Across the full history, 61 open-market purchases and 204 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on ACAD insider trades is 59.6/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live ACAD trades on FilingIQ Raw filings on SEC EDGAR

Latest ACAD Form 4 filings

Owen Adams Catherine Chief Executive Officer

KIM AUSTIN D. EVP,General Counsel, Secretary

S Oct 6, 2023

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

Top insiders trading ACAD

Owen Adams Catherine

5 trades · score 74.0

13F funds holding ACAD

Frazier Life Sciences Management, L.P.

$13.65M · 0.8% of AUM

Frequently asked

How many insider trades does FilingIQ track for ACAD?: FilingIQ tracks 684 Form 4 insider transactions for ACAD (ACADIA PHARMACEUTICALS INC), covering filings from Jan 13, 2015 onwards. 51 of those were filed in the last 90 days.
Are ACAD insiders net buyers or net sellers?: Across the full Form 4 history for ACAD, 61 transactions (9%) were open-market purchases and 204 (30%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does ACAD insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is ACAD in?: ACADIA PHARMACEUTICALS INC (ACAD) is classified in the Healthcare sector, specifically Biotechnology, with a current market capitalisation of $4.18B.

Methodology & sources

Every ACAD insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.